Pacific Bio (NASDAQ: PACB) reported Q3 EPS of ($0.17), $0.05 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $40 million versus the consensus estimate of $41.95 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.